International Mammalian Genome Society

The 16th International Mouse Genome Conference (2002)

Plenary Presentations * Oral Presentations *
Poster Presentations: Complex Genetics and Disease Modifiers * Developmental Genetics * Functional Genomics * Gene Discovery * Genetic Manipulations to Alter Gene Function * Mouse Models: Human Disease and Pharmacogenetics * Sequence Annotation and Comparative Analysis of Genomes *
Attendees * Sponsors * Table of Contents * Photographs * Awards

POSTER 133 - DEVELOPMENT OF BLOOD TEST SYSTEM FOR ENU MUTAGENESIS PROJECT IN RIKEN GSC

H Motegi
Mouse Functional Genomics Research Group, RIKEN GSC

1) Toki H, 2) Ohtaki M, 2) Satoh K, 1) Masuya H, 1) Inoue M, 1) Suzuki T, 1) Kobayashi K, 1) Wakana S, 3) Gondo Y, 1) Minowa O, 1) Shiroishi T, 1) Noda T
1) Mouse Functional Genomics Research Group, RIKEN GSC, 2) Department of Environmetrics and Biometrics, Research Institute for Radiation Biology and Medicine, Hiroshima University, 3) Population and Quantitative Genomics Team, RIKEN GSC

To identify mouse models of human diseases, we have established blood test system for screening mutagenized offspring and confirming of heritability of mutant in RIKEN ENU mutagenesis project. This blood test system consists of hematological test and clinical biochemical test. For hematological test, about 200 micro-L of blood per mouse is collected at the age of 9 weeks and 32 parameters were measured by automatic hematology analyzer ADVIA120 (Bayer). Using a statistical method with mixed normal models, we determined normal ranges of these parameters to identify outliers. For clinical biochemical test, blood is collected at the age of 11 weeks. About 75 micro-L of serum is separated from the collected blood and applied to automatic clinical biochemical analyzer JCA-BM2250 (JEOL). Using a similar way in hematological test, normal ranges of 30 parameters were determined.For each test, we have screened about 8500 mice and found more than twenty traits of mutants inherited. As initial step of characterization to obtain further information on those phenotypes, we are currently analyzing mutants in more details.Recently we have started the screening on late onset stage to find mutants those related to age-dependent disease and common disease such as hyperlipemia, arteriosclerosis, or diabetes. In this poster, we will report the progress of early and late onset screening by our blood test system.